Canadians prescribed the antipsychotic drug Rexulti have until August 27 to file a claim in a $4.75-million class-action settlement. The lawsuit alleges the medication caused compulsive behaviors, including gambling, shopping, and binge-eating, in patients treated since February 2017.
Who Qualifies for the Rexulti Settlement?
The class action covers individuals who were prescribed Rexulti—used to treat schizophrenia and depression—and later developed impulse-control disorders. Quebec Superior Court approved the settlement in November 2023, following a national lawsuit against manufacturers Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.
Compensation amounts vary, with payouts ranging from approximately $6,500 for mild cases to over $102,000 for severe impacts. Lawyers representing plaintiffs have described the settlement as a compromise, with no admission of liability from the drugmakers.
How to File a Claim Before the Deadline
Eligible Canadians must submit their claims by 11:59 p.m. on August 27 to receive a share of the settlement. The process requires documentation of Rexulti prescriptions and evidence of related compulsive behaviors. Further details, including claim forms, are available through the lawsuit’s official website.
Failure to file by the deadline will result in forfeiture of any potential compensation under the settlement terms.
Background on the Rexulti Lawsuit
The class action was authorized in November 2022, nearly a year before the settlement received court approval. The case centered on allegations that Rexulti’s side effects—particularly impulse-control disorders—were not adequately disclosed to patients or healthcare providers.
While the settlement resolves the legal dispute, it does not establish wrongdoing by Otsuka or Lundbeck. Both companies have denied liability but agreed to the financial resolution to avoid prolonged litigation.
